-
Mashup Score: 2
Early relapse following autologous hematopoietic stem cell transplant (auto-HSCT) is associated with a poor prognosis, as are high-risk cytogenetic features and failure to achieve a complete response. During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Beksac discussed developing a scoring system to predict early relapse following auto-HSCT for patients with multiple myeloma (MM) in the EBMT database who were treated with 200 mg/m2 melphalan (Mel200) or 140 mg/m2 melphalan (Mel140).
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Morie A. Gertz, Mayo Clinic, Rochester, US. We asked, In the era of upfront quadruplets, is there still a role for tandem transplant?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 Have you seen this? During the #EBMT22, the MM Hub was pleased to speak to @MorieGertz, @MayoClinic. We asked, In the era of upfront quadruplets, is there still a role for tandem transplant? 👇 #mmsm #myeloma https://t.co/taFSTmm0jJ
-
-
Mashup Score: 0
Early relapse following autologous hematopoietic stem cell transplant (auto-HSCT) is associated with a poor prognosis, as are high-risk cytogenetic features and failure to achieve a complete response. During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Beksac discussed developing a scoring system to predict early relapse following auto-HSCT for…
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Have you seen this❓ @mbeksac56 discussed a new scoring system for risk of early relapse in patients with #myeloma at #EBMT22. Find the write-up here, with a closer look at high-risk patients. 👉 https://t.co/dGHB5elAXf 👈 #mmsm #bmtsm @EBMT https://t.co/fByBSnr4So
-
-
Mashup Score: 1
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), a joint session titled “Access to novel cell therapies such as CAR T cells: challenges and strategies” was delivered by several speakers. Here, we present perspectives from different countries, including the US, Europe, Asia, and Latin America.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Have you seen this❓ 🌍 A global perspective on current barriers and future directions for access to #CARTcells was provided during the latest @EBMT congress. Read more in our article on the MM Hub 👉 https://t.co/H032vqzHnX 👈 #EBMT22 #bmtsm #mmsm
-
-
Mashup Score: 0
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Nina Shah, UCSF, San Francisco, US. We asked, What factors correlate with a better response to BCMA-directed CAR T-cell products?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Have you seen this? 🎥 During #EBMT22, the Multiple Myeloma Hub was pleased to speak to @ninashah33, UCSF. We asked, What factors correlate with a better response to BCMA-directed CAR T-cell products? 👉 https://t.co/ZnlvNq28t4 👈 #mmsm #myeloma
-
-
Mashup Score: 1How can MRD assessment help when treating patients with high-risk MM after transplantation? - 2 year(s) ago
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Elena Zamagni, University of Bologna, Bologna, IT. We asked, How can MRD assessment help when treating patients with high-risk MM after transplantation?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Have you watched this❓ 🎥 During #EBMT22, the MM Hub was pleased to speak to Elena Zamagni, University of Bologna. We asked, How can MRD assessment help when treating patients with high-risk MM after transplantation? 👉 https://t.co/2fbrjX7sHj 👈 #mmsm #myeloma
-
-
Mashup Score: 3Conditioning regimens prior to allo-HSCT: Updates from the 48th Annual Meeting of the EBMT (2022) - 2 year(s) ago
At the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the safety and efficacy of conditioning combinations were evaluated for patients undergoing allo-HSCT, using data from the Acute Leukemia Working Party (ALWP) of the EBMT. We summarize results from four key talks below.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📚Weekend read: Read our summary of the latest data on safety and efficacy of conditioning regimens prior to allo-HSCT with data from the ALWP of the EBMT 👉 https://t.co/eNXqAfzIdG 👈 #EBMT22 #leusm #aml #AMLsm https://t.co/0sWU8HWmTY
-
-
Mashup Score: 1
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Morie A. Gertz, Mayo Clinic, Rochester, US. We asked, In the era of upfront quadruplets, is there still a role for tandem transplant?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 Did you see this from #EBMT22 The MM Hub was pleased to speak to @MorieGertz, @MayoClinic. We asked, In the era of upfront quadruplets, is there still a role for tandem transplant? 👉 https://t.co/taFSTmDBbh 👈 #MMSM #multiplemyeloma #myeloma
-
-
Mashup Score: 5
Early relapse following autologous hematopoietic stem cell transplant (auto-HSCT) is associated with a poor prognosis, as are high-risk cytogenetic features and failure to achieve a complete response. During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Beksac discussed developing a scoring system to predict early relapse following auto-HSCT for…
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Have you read this yet❓ @mbeksac56 discussed a new scoring system for risk of early relapse in patients with #myeloma at #EBMT22. 📝 Find the write-up here, with a closer look at high-risk patients. 👇 👉 https://t.co/dGHB5e3rJ7 👈 #mmsm #bmtsm @EBMT https://t.co/ZM5OO3T1lL
-
-
Mashup Score: 4
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Morie A. Gertz, Mayo Clinic, Rochester, US. We asked, In the era of upfront quadruplets, is there still a role for tandem transplant?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 During the #EBMT22, the MM Hub was pleased to speak to @MorieGertz, @MayoClinic. We asked, In the era of upfront quadruplets, is there still a role for tandem transplant? 👇 #mmsm #myeloma https://t.co/taFSTmm0jJ
-
Have you read this yet? @mbeksac56 discussed a new scoring system for risk of early relapse in patients with #myeloma at #EBMT22. 📝 Find the write-up here, with a closer look at high-risk patients. 👇 👉 https://t.co/dGHB5el37H 👈 #mmsm #bmtsm @EBMT #EBMT23 https://t.co/lz3dYidGh9